RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > When the FDA Inspector Comes, What are the Chances of a Really Bad Outcome?

When the FDA Inspector Comes, What are the Chances of a Really Bad Outcome?

Posted 21 October 2014 | By Sharon DeGrove Bishop, RAC

When the FDA Inspector Comes, What are the Chances of a Really Bad Outcome?

Regulatory intelligence is at the heart of every well-informed regulatory decision, and is integral to maximizing effectiveness and influence for the regulatory professional.   The Regulatory Intelligence Quotient is a regular exploration of regulatory intelligence topics by thought leaders in the field. Want to learn more or suggest future topics? Contact us at asksofie@graematter.com

It’s generally nerve-wracking when the US Food and Drug Administration (FDA) shows up at your door for an inspection. Even if you’re confident that everything is in good shape, the specter of Murphy’s Law lurks around every corner. 

To ensure compliance with regulations, the FDA conducts inspections of all registered establishments. Once the inspection is closed out, it is categorized in one of three ways based on the objectionable conditions noted (if any):

  • NAI - No Action Indicated
  • VAI - Voluntary Action Indicated
  • OAI - Official Action Indicated

NAI and VAI indicate that only minor objections were noted, whereas OAI indicates that significant objectionable conditions that warrant FDA sanctions were cited. So it’s the OAI inspections that make the headlines, and that no one wants to experience first-hand, but how often do these occur?

Using The SOFIETM System for Regulatory Intelligence, we took a look at the data. The chart below shows the number of NAI, VAI and OAI outcomes for all US FDA districts for the years 2009-2013. These are inspections of all FDA-regulated industries including drugs, devices, biologics, veterinary, food and cosmetics.

FDA Inspections by District

* Note that there are possibly some inspections from 2013 that have yet to be closed out and so these numbers may be incomplete.

It’s clear that each year the bulk of inspections end up being NAI or VAI, and relatively few inspections meet the requirements for OAI. Also, note the peak in the number of inspections in 2011. A closer look at the numbers of OAI inspections better demonstrates the variability from year to year:

FDA Inspections - OAI District Decisions

If we consider the percentage of inspections that are classified as OAI, we find that it’s fewer than 4%. It’s also apparent that the percentage of inspections that receive the NAI classification is increasing over time, while both VAI and OAI are decreasing slightly.

FDA District Decisions for Inspections

While this provides an average rate for the entire country (all FDA districts), it’s not necessarily consistent from one district to another. Let’s consider some particular districts over that same period of time. For this analysis, we looked at the percentage of OAI findings for five districts that conduct a lot of inspections, specifically:

  • Atlanta (ATL)
  • Dallas (DAL)
  • Los Angeles (LOS)
  • Minneapolis (MIN)
  • New England (NWE)

FDA Inspection District Decision (OAI) for Five Districts

Here we see that in 2009 the Los Angeles district had roughly twice the rate of OAI outcomes as compared to the other districts, but that it has since decreased to a more comparable rate. Note the interesting blips in Dallas in 2012 and Minneapolis in 2011. And while 2013 showed an increase in the rate of OAI for the New England district, the remaining four districts all showed decreasing rates, following the trend for all districts.

Would you like to know what’s going on in your district? Send us an email at asksofie@graematter.com with your requests. Let us know what you think. To contact us with your thoughts or to request more information, email asksofie@graematter.com or connect with us on LinkedIn, Twitter and Facebook.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.